ENXTPA:VIRP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. More Details


Snowflake Analysis

Excellent balance sheet with solid track record.


Similar Companies

Share Price & News

How has Virbac's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VIRP is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: VIRP's weekly volatility (5%) has been stable over the past year.


Market Performance


7 Day Return

3.7%

VIRP

-2.4%

FR Pharmaceuticals

0.4%

FR Market


1 Year Return

-2.5%

VIRP

-1.8%

FR Pharmaceuticals

-3.0%

FR Market

Return vs Industry: VIRP matched the French Pharmaceuticals industry which returned -1.7% over the past year.

Return vs Market: VIRP matched the French Market which returned -2.7% over the past year.


Shareholder returns

VIRPIndustryMarket
7 Day3.7%-2.4%0.4%
30 Day-1.6%1.3%13.2%
90 Day14.4%-2.3%11.0%
1 Year-2.5%-2.5%1.5%-1.8%-1.0%-3.0%
3 Year95.4%95.4%19.9%6.9%16.6%6.9%
5 Year9.2%9.2%23.3%2.3%44.5%24.8%

Long-Term Price Volatility Vs. Market

How volatile is Virbac's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Virbac undervalued compared to its fair value and its price relative to the market?

24.86x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: VIRP (€213) is trading above our estimate of fair value (€194.66)

Significantly Below Fair Value: VIRP is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: VIRP is poor value based on its PE Ratio (24.9x) compared to the XE Pharmaceuticals industry average (23.1x).

PE vs Market: VIRP is poor value based on its PE Ratio (24.9x) compared to the French market (21.1x).


Price to Earnings Growth Ratio

PEG Ratio: VIRP is poor value based on its PEG Ratio (13.8x)


Price to Book Ratio

PB vs Industry: VIRP's PB Ratio (3.3x) is in line with the FR Pharmaceuticals industry average.


Next Steps

Future Growth

How is Virbac forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

1.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIRP's forecast earnings growth (1.8% per year) is above the savings rate (0.6%).

Earnings vs Market: VIRP's earnings (1.8% per year) are forecast to grow slower than the French market (25.2% per year).

High Growth Earnings: VIRP's earnings are forecast to grow, but not significantly.

Revenue vs Market: VIRP's revenue (2.7% per year) is forecast to grow slower than the French market (7.2% per year).

High Growth Revenue: VIRP's revenue (2.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: VIRP's Return on Equity is forecast to be low in 3 years time (9.4%).


Next Steps

Past Performance

How has Virbac performed over the past 5 years?

20.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VIRP has high quality earnings.

Growing Profit Margin: VIRP's current net profit margins (7.6%) are higher than last year (3.8%).


Past Earnings Growth Analysis

Earnings Trend: VIRP's earnings have grown significantly by 20.1% per year over the past 5 years.

Accelerating Growth: VIRP's earnings growth over the past year (110.3%) exceeds its 5-year average (20.1% per year).

Earnings vs Industry: VIRP earnings growth over the past year (110.3%) exceeded the Pharmaceuticals industry 13.2%.


Return on Equity

High ROE: VIRP's Return on Equity (13.1%) is considered low.


Next Steps

Financial Health

How is Virbac's financial position?


Financial Position Analysis

Short Term Liabilities: VIRP's short term assets (€788.3M) exceed its short term liabilities (€345.1M).

Long Term Liabilities: VIRP's short term assets (€788.3M) exceed its long term liabilities (€414.1M).


Debt to Equity History and Analysis

Debt Level: VIRP's debt to equity ratio (74.7%) is considered high.

Reducing Debt: VIRP's debt to equity ratio has reduced from 140.7% to 74.7% over the past 5 years.

Debt Coverage: VIRP's debt is well covered by operating cash flow (33.8%).

Interest Coverage: VIRP's interest payments on its debt are well covered by EBIT (10x coverage).


Balance Sheet


Next Steps

Dividend

What is Virbac current dividend yield, its reliability and sustainability?

0.89%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VIRP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VIRP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VIRP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VIRP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: VIRP is not paying a notable dividend for the French market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VIRP's dividend in 3 years as they are not forecast to pay a notable one for the French market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.4yrs

Average management tenure


CEO

Sébastien Huron (49 yo)

2.92yrs

Tenure

€555,361

Compensation

Mr. Sébastien Huron has been Chairman of Executive Board at Virbac SA since December 20, 2017. He served as the Head of Global Business Operations at Virbac SA since 2014 and has been its Member of Executi...


CEO Compensation Analysis

Compensation vs Market: Sébastien's total compensation ($USD661.38K) is below average for companies of similar size in the French market ($USD949.80K).

Compensation vs Earnings: Sébastien's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sébastien Huron
Chairman of the Executive Board2.92yrs€555.36k0.011%
€ 206.5k
Habib Ramdani
CFO & Member of Executive Board4.42yrs€298.77kno data
Christian Karst
Executive VP of Corporate Development23.92yrs€1.15m0.066%
€ 1.2m
Sandrine Brunel
Head of Corporate Communicationsno datano datano data
Francesca Cortella
Head of Corporate Human Resourcesno datano datano data
Marc Bistuer
Head of Global Industrial Operations & Corporate Quality Assuranceno datano datano data
Manuela Rodríguez
Director of Financial Projectsno datano datano data

4.4yrs

Average Tenure

49yo

Average Age

Experienced Management: VIRP's management team is considered experienced (4.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Olivier Bohuon
Independent Member of the Supervisory Board9.83yrs€21.00k0.00012%
€ 2.2k
Pierre Madelpuech
Vice Chairman of Supervisory Boardno data€21.00k0.0013%
€ 23.4k
Marie-Hélène Dick-Madelpuech
Chairwoman of Supervisory Board14.58yrs€116.00k49.8%
€ 894.8m
Xavier Yon
Non-Voting Advisorno data€21.00kno data
Philippe Gaston Capron
Independent Member of the Supervisory Board16.83yrs€24.00k0.0052%
€ 94.2k
Cyrille Petit
Independent Member of Supervisory Board1.42yrsno data0.00012%
€ 2.2k
Solène Madelpuech
Member of Supervisory Board3.17yrs€21.00k0.00012%
€ 2.2k
Sylvie Gueguen
Employee Representative of Supervisory Board2.83yrsno datano data

6.5yrs

Average Tenure

57yo

Average Age

Experienced Board: VIRP's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Virbac SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Virbac SA
  • Ticker: VIRP
  • Exchange: ENXTPA
  • Founded: 1968
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €1.797b
  • Shares outstanding: 8.44m
  • Website: https://corporate.virbac.com

Number of Employees


Location

  • Virbac SA
  • 13e rue LID - BP 27
  • Cedex
  • Carros
  • Provence-Alpes-Côte d'Azur
  • 6511
  • France

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VIRPENXTPA (Euronext Paris)YesShare CapitalFREURJan 1992
0NM7LSE (London Stock Exchange)YesShare CapitalGBEURJan 1992
VRBC.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDJan 1992
V16DB (Deutsche Boerse AG)YesShare CapitalDEEURJan 1992
VIRPPBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBEURJan 1992

Biography

Virbac SA produces and sells medicines and vaccines for companion and food-producing animals in France and internationally. The company offers Anibidiol, a food supplement in powder/granulate form; Alizine...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/25 22:10
End of Day Share Price2020/11/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.